I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients.
folfiri regimen
BRAF
metastasis
measurable disease
adjuvant chemotherapy
- 0 views
- 16 Feb, 2024
- 1 location